Ramakrishnan Sabitha, Partricia Steena, Mathan Ganeshan
Bharathidasan University, Tiruchirappalli 620024, Tamilnadu, India.
Bharathidasan University, Tiruchirappalli 620024, Tamilnadu, India.
Biomed Pharmacother. 2015 Mar;70:103-10. doi: 10.1016/j.biopha.2014.12.041. Epub 2015 Jan 12.
As general, the Human papillomavirus (HPV) causes the most sexually transmitted diseases. Among well categorized 80 types, the high-risk types HPV's 16 and 18 are highly involved in 70% of cervical cancer. The virulence of HPV is mainly exhibited by E5, E6 and E7 encoded oncoproteins that cause low to high-grade cervical lesions (CIN-1, 2, 3), leading to form 99.7% of squamous cell and 89% of adenocarcinomas cervical cancer worldwide. This study mainly encircles the major role of E5, E6 and E7 oncoproteins in HPV 16 and 18. Further discussed the uprising of significant biomarkers and their cellular process in different stages of cervical cancer with current prevention and treatment regimens. Hence, this integration will evoke novel markers, potential vaccination and various treatments approaches with special reference for HPV16 and 18 infected cervical cancers.
一般来说，人乳头瘤病毒（HPV）引发的性传播疾病最为常见。在已明确分类的80种HPV类型中，高危型HPV 16和18型与70%的宫颈癌高度相关。HPV的毒性主要通过E5、E6和E7编码的癌蛋白表现出来，这些蛋白会导致低度到高度的宫颈病变（CIN-1、2、3），在全球范围内引发99.7%的鳞状细胞宫颈癌和89%的腺癌宫颈癌。本研究主要围绕E5、E6和E7癌蛋白在HPV 16和18型中的主要作用展开。进一步探讨了宫颈癌不同阶段重要生物标志物的出现及其细胞过程，以及当前的预防和治疗方案。因此，这种整合将引发新的标志物、潜在疫苗和各种治疗方法，特别是针对HPV16和18感染的宫颈癌。
Biomed Pharmacother. 2015-3
Gynecol Oncol. 2013-9-5
World J Clin Oncol. 2025-5-24
Zotero 插件